ERBB2 and breast carcinoma: The development of new drugs for managing breast cancer has led to longer life-spans for women with some types of Stage IV disease, such ER+ and Her2+ subtypes, but less so for others, including those with BRCA1/2 wildtype triple negative (TN) disease [1, 2].